Claire Manuszak, BS, discusses a phase I study (NCT03495323) with prexasertib (LY2606368) and LY3300054 in ovarian cancer.
Claire Manuszak, BS
Advertisement
Articles by Claire Manuszak, BS
Claire Manuszak, BS, discusses the rationale to combine prexasertib (LY2606368) and LY3300054 in patients with high-grade serous ovarian cancer.
Advertisement
Latest Updated Articles
The Rationale to Combine Prexasertib With LY3300054 in Ovarian CancerPublished: February 11th 2020 | Updated:
Phase I Study With Prexasertib and LY3300054 in Ovarian CancerPublished: March 6th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5